Nektar Therapeutics (NKTR)

Price$57.32

Value ScoreC

Growth ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-20.02%

Price vs S&P 500 (4W)-29.99%

VGM Score44.91

Market Capitalization$1.94B

All Metrics

Book Value / Share (Quarterly)$19.55

P/TBV (Annual)2.92x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-15.67%

Cash Flow / Share (Quarterly)$-6.94

Price vs S&P 500 (YTD)27.41%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-280.80%

EPS (TTM)$-8.32

10-Day Avg Trading Volume1.06M

EPS Excl Extra (TTM)$-8.32

Revenue Growth (5Y)-18.43%

EPS (Annual)$-9.73

ROI (Annual)-107.25%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-327.61%

Cash / Share (Quarterly)$19.29

Revenue Growth QoQ (YoY)3.83%

ROA (Last FY)-58.51%

Revenue Growth TTM (YoY)-36.24%

EBITD / Share (TTM)$-6.86

ROE (5Y Avg)-153.36%

Operating Margin (TTM)-241.98%

Cash Flow / Share (Annual)$-10.27

P/B Ratio3.36x

P/B Ratio (Quarterly)3.58x

Net Income / Employee (Annual)$-2,604,400

EV / Revenue (TTM)33.21x

Net Interest Coverage (TTM)-8.87x

ROA (TTM)-40.25%

EV / EBITDA (TTM)2.78x

EPS Incl Extra (Annual)$-9.73

Current Ratio (Annual)4.97x

Quick Ratio (Quarterly)9.92x

3-Month Avg Trading Volume1.16M

52-Week Price Return470.35%

Revenue / Employee (TTM)$883,100

Tangible BV / Share (Quarterly)$1.15

P/S Ratio (Annual)35.06x

Asset Turnover (Annual)0.20x

52-Week High$109.00

Operating Margin (5Y Avg)-299.88%

EPS Excl Extra (Annual)$-9.73

CapEx CAGR (5Y)-34.68%

Tangible BV CAGR (5Y)2.06%

26-Week Price Return-12.10%

Quick Ratio (Annual)4.62x

13-Week Price Return-20.88%

Total Debt / Equity (Annual)0.70x

Current Ratio (Quarterly)10.21x

Enterprise Value$1.85B

Revenue / Share Growth (5Y)30.77%

Asset Turnover (TTM)0.14x

Book Value / Share Growth (5Y)-5.92%

Revenue / Employee (Annual)$876,700

Inventory Turnover (Annual)3.81x

Pretax Margin (Annual)-281.52%

Cash / Share (Annual)$12.06

3-Month Return Std Dev61.16%

Gross Margin (5Y Avg)76.67%

Net Income / Employee (TTM)$-2,479,700

ROE (Last FY)-182.65%

Net Interest Coverage (Annual)-7.77x

EPS Basic Excl Extra (Annual)$-9.73

P/FCF (TTM)1.85x

Receivables Turnover (TTM)163.36x

Total Debt / Equity (Quarterly)0.10x

EPS Incl Extra (TTM)$-8.32

Receivables Turnover (Annual)163.36x

ROI (TTM)-36.21%

P/S Ratio (TTM)34.81x

Pretax Margin (5Y Avg)-323.80%

Revenue / Share (Annual)$3.27

Tangible BV / Share (Annual)$2.29

Price vs S&P 500 (52W)445.98%

Year-to-Date Return35.57%

5-Day Price Return-10.24%

EPS Normalized (Annual)$-9.73

ROA (5Y Avg)-53.15%

Net Profit Margin (Annual)-297.07%

Month-to-Date Return-11.65%

Cash Flow / Share (TTM)$-1.50

EBITD / Share (Annual)$-8.24

Operating Margin (Annual)-253.66%

LT Debt / Equity (Annual)0.70x

ROI (5Y Avg)-95.22%

LT Debt / Equity (Quarterly)0.10x

EPS Basic Excl Extra (TTM)$-8.32

P/TBV (Quarterly)3.11x

P/B Ratio (Annual)9.57x

Inventory Turnover (TTM)3.81x

Pretax Margin (TTM)-273.59%

Book Value / Share (Annual)$4.41

Price vs S&P 500 (13W)-29.14%

Beta1.16x

P/FCF (Annual)2.75x

Revenue / Share (TTM)$2.25

ROE (TTM)-45.78%

52-Week Low$7.99

vGradeC

gGradeD

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-1.82est. -1.63

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.29

4.31

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
NKTRNektar Therapeutics	C	D	C	$57.32
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Nektar Therapeutics is a biopharmaceutical company developing immunotherapy medicines in clinical development. Its pipeline includes REZPEG (NKTR-358), NKTR-422, NKTR-0165, and NKTR-255, among other candidates. The company focuses on discovering and developing novel therapeutics to address unmet medical needs in immunology.